Hema Now | Episode 12
This week, Jonathan is joined by Xavier Leleu, world-renowned expert in multiple myeloma, Waldenström’s macroglobulinemia, and amyloidosis. The pair discuss groundbreaking advances in clinical trials and the future of myeloma immunotherapy.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (31 mins)
Xavier Leleu
Xavier Leleu is Professor, Head of the Myeloma Clinic, and Head of the Department of Hematology at Centre Hospitalier Universitaire (CHU) at Université de Poitiers, France. Leleu received his medical degree from the University of Bordeaux, France, a Master’s in cellular biology from the University of Medicine of Lille, France, and a PhD from the Dana-Farber Cancer Institute in Boston, USA. He was Head of the Myeloma Clinic in Lille for almost 15 years.
Leleu’s research is focused on the biology and treatment of multiple myeloma, Waldenström’s macroglobulinemia, and amyloidosis. He is actively involved in numerous national and international clinical trials as an investigator and coordinator.
Timestamps:
00:00 – Introduction
00:59 – Clinical trial breakthroughs in transplant-ineligible myeloma
03:38 – Minimal residual disease: a key endpoint
05:21 – Rethinking therapeutic strategies in myeloma
10:58 – Challenges in late-line myeloma therapies
13:54 – T-cell-engaging bispecific antibodies
17:41 – Waldenström’s macroglobulinemia and amyloidosis
21:50 – What’s next in multiple myeloma treatment?
24:43 – Xavier’s three wishes for healthcare
